ID   CP19A_HUMAN             Reviewed;         503 AA.
AC   P11511; Q16731; Q3B764; Q58FA0; Q8IYJ7;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Aromatase;
DE            EC=1.14.14.14 {ECO:0000269|PubMed:27702664};
DE   AltName: Full=CYPXIX;
DE   AltName: Full=Cytochrome P-450AROM;
DE   AltName: Full=Cytochrome P450 19A1;
DE   AltName: Full=Estrogen synthase;
GN   Name=CYP19A1; Synonyms=ARO1, CYAR, CYP19;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2973313; DOI=10.1016/S0006-291X(88)80903-3;
RA   Harada N.;
RT   "Cloning of a complete cDNA encoding human aromatase: immunochemical
RT   identification and sequence analysis.";
RL   Biochem. Biophys. Res. Commun. 156:725-732(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3390233; DOI=10.1089/dna.1988.7.27;
RA   Chen S., Besman M.J., Sparkes R.S., Zollman S., Klisak I.,
RA   Mohandas T., Hall P.F., Shively J.E.;
RT   "Human aromatase: cDNA cloning, Southern blot analysis, and assignment
RT   of the gene to chromosome 15.";
RL   DNA 7:27-38(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CYS-264.
RX   PubMed=2848247; DOI=10.1073/pnas.85.23.8948;
RA   Corbin C.J., Graham-Lorence S., McPhaul M., Mason J.I.,
RA   Mendelson C.R., Simpson E.R.;
RT   "Isolation of a full-length cDNA insert encoding human aromatase
RT   system cytochrome P-450 and its expression in nonsteroidogenic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:8948-8952(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2541021; DOI=10.1016/0014-5793(89)81373-0;
RA   Toda K., Terashima M., Mitsuuchi Y., Yamasaki Y., Yokoyama Y.,
RA   Nojima S., Ushiro H., Maeda T., Yamamoto Y., Sagara Y., Shizuta Y.;
RT   "Alternative usage of different poly(A) addition signals for two major
RT   species of mRNA encoding human aromatase P-450.";
RL   FEBS Lett. 247:371-376(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2808431;
RA   Means G.D., Mahendroo M.S., Corbin C.J., Mathis J.M., Powell F.E.,
RA   Mendelson C.R., Simpson E.R.;
RT   "Structural analysis of the gene encoding human aromatase cytochrome
RT   P-450, the enzyme responsible for estrogen biosynthesis.";
RL   J. Biol. Chem. 264:19385-19391(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2691883; DOI=10.1210/mend-3-9-1477;
RA   Pompon D., Liu R.Y., Besman M.J., Wang P.L., Shively J.E., Chen S.;
RT   "Expression of human placental aromatase in Saccharomyces
RT   cerevisiae.";
RL   Mol. Endocrinol. 3:1477-1487(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1371509;
RA   Harada N., Ogawa H., Shozu M., Yamada K., Suhara K., Nishida E.,
RA   Takagi Y.;
RT   "Biochemical and molecular genetic analyses on placental aromatase (P-
RT   450AROM) deficiency.";
RL   J. Biol. Chem. 267:4781-4785(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-39; MET-201 AND
RP   CYS-264.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   MET-201.
RC   TISSUE=Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-503 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=3018730; DOI=10.1073/pnas.83.17.6387;
RA   Evans C.T., Ledesma D.B., Schulz T.Z., Simpson E.R., Mendelson C.R.;
RT   "Isolation and characterization of a complementary DNA specific for
RT   human aromatase-system cytochrome P-450 mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6387-6391(1986).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-503 (ISOFORM 1), AND VARIANT CYS-264.
RX   PubMed=3653507; DOI=10.1016/0303-7207(87)90054-2;
RA   Simpson E.R., Evans C.T., Corbin C.J., Powell F.E., Ledesma D.B.,
RA   Mendelson C.R.;
RT   "Sequencing of cDNA inserts encoding aromatase cytochrome P-450 (P-
RT   450AROM).";
RL   Mol. Cell. Endocrinol. 52:267-272(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49, AND TISSUE SPECIFICITY.
RX   PubMed=2040633;
RA   Mahendroo M.S., Means G.D., Mendelson C.R., Simpson E.R.;
RT   "Tissue-specific expression of human P-450AROM. The promoter
RT   responsible for expression in adipose tissue is different from that
RT   utilized in placenta.";
RL   J. Biol. Chem. 266:11276-11281(1991).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49, TISSUE SPECIFICITY, AND
RP   ALTERNATIVE PROMOTER USAGE.
RX   PubMed=7690033;
RA   Mahendroo M.S., Mendelson C.R., Simpson E.R.;
RT   "Tissue-specific and hormonally controlled alternative promoters
RT   regulate aromatase cytochrome P450 gene expression in human adipose
RT   tissue.";
RL   J. Biol. Chem. 268:19463-19470(1993).
RN   [15]
RP   PRELIMINARY PROTEIN SEQUENCE OF N-TERMINUS.
RC   TISSUE=Placenta;
RX   PubMed=3964273; DOI=10.1016/0006-291X(86)90987-3;
RA   Chen S., Shively J.E., Nakajin S., Shinoda M., Hall P.F.;
RT   "Amino terminal sequence analysis of human placenta aromatase.";
RL   Biochem. Biophys. Res. Commun. 135:713-719(1986).
RN   [16]
RP   ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY.
RX   PubMed=8117272; DOI=10.1006/bbrc.1994.1163;
RA   Honda S., Harada N., Takagi Y.;
RT   "Novel exon 1 of the aromatase gene specific for aromatase transcripts
RT   in human brain.";
RL   Biochem. Biophys. Res. Commun. 198:1153-1160(1994).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) IN COMPLEX WITH ANDROSTENEDIONE,
RP   AND HEME.
RX   PubMed=19129847; DOI=10.1038/nature07614;
RA   Ghosh D., Griswold J., Erman M., Pangborn W.;
RT   "Structural basis for androgen specificity and oestrogen synthesis in
RT   human aromatase.";
RL   Nature 457:219-223(2009).
RN   [18]
RP   VARIANTS AROD CYS-435 AND TYR-437.
RX   PubMed=8265607; DOI=10.1073/pnas.90.24.11673;
RA   Ito Y., Fisher C.R., Conte F.A., Grumbach M.M., Simpson E.R.;
RT   "Molecular basis of aromatase deficiency in an adult female with
RT   sexual infantilism and polycystic ovaries.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:11673-11677(1993).
RN   [19]
RP   VARIANT AROD CYS-375.
RX   PubMed=8530621; DOI=10.1210/jcem.80.12.8530621;
RA   Morishima A., Grumbach M.M., Simpson E.R., Fisher C., Qin K.;
RT   "Aromatase deficiency in male and female siblings caused by a novel
RT   mutation and the physiological role of estrogens.";
RL   J. Clin. Endocrinol. Metab. 80:3689-3698(1995).
RN   [20]
RP   VARIANT AROD GLN-365.
RX   PubMed=9211678; DOI=10.1056/NEJM199707103370204;
RA   Carani C., Qin K., Simoni M., Faustini-Fustini M., Serpente S.,
RA   Boyd J., Korach K.S., Simpson E.R.;
RT   "Effect of testosterone and estradiol in a man with aromatase
RT   deficiency.";
RL   N. Engl. J. Med. 337:91-95(1997).
RN   [21]
RP   VARIANT CYS-264.
RX   PubMed=9352581;
RA   Watanabe J., Harada N., Suemasu K., Higashi Y., Gotoh O., Kawajiri K.;
RT   "Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene
RT   does not affect aromatase activity.";
RL   Pharmacogenetics 7:419-424(1997).
RN   [22]
RP   VARIANTS ARG-39 AND CYS-264.
RX   PubMed=10956405;
RX   DOI=10.1002/1097-0215(20000720)89:4<325::AID-IJC2>3.0.CO;2-3;
RA   Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S.;
RT   "Breast cancer risk associated with polymorphism in CYP19 in Japanese
RT   women.";
RL   Int. J. Cancer 89:325-328(2000).
RN   [23]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-375.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [24]
RP   VARIANT AROD HIS-192, AND CHARACTERIZATION OF VARIANT AROD HIS-192.
RX   PubMed=24705274; DOI=10.1016/j.mce.2014.03.008;
RA   Bouchoucha N., Samara-Boustani D., Pandey A.V., Bony-Trifunovic H.,
RA   Hofer G., Aigrain Y., Polak M., Fluck C.E.;
RT   "Characterization of a novel CYP19A1 (aromatase) R192H mutation
RT   causing virilization of a 46,XX newborn, undervirilization of the
RT   46,XY brother, but no virilization of the mother during pregnancies.";
RL   Mol. Cell. Endocrinol. 390:8-17(2014).
RN   [25]
RP   CHARACTERIZATION OF VARIANTS CYS-264 AND HIS-264, PHOSPHORYLATION,
RP   CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=27702664; DOI=10.1016/j.jsbmb.2016.09.022;
RA   Baravalle R., Di Nardo G., Bandino A., Barone I., Catalano S.,
RA   Ando S., Gilardi G.;
RT   "Impact of R264C and R264H polymorphisms in human aromatase
RT   function.";
RL   J. Steroid Biochem. Mol. Biol. 167:23-32(2017).
CC   -!- FUNCTION: Catalyzes the formation of aromatic C18 estrogens from
CC       C19 androgens.
CC   -!- CATALYTIC ACTIVITY: Testosterone + 3 [reduced NADPH--hemoprotein
CC       reductase] + 3 O(2) = 17-beta-estradiol + formate + 4 H(2)O + 3
CC       [oxidized NADPH--hemoprotein reductase].
CC       {ECO:0000269|PubMed:27702664}.
CC   -!- CATALYTIC ACTIVITY: Androst-4-ene-3,17-dione + 3 [reduced NADPH--
CC       hemoprotein reductase] + 3 O(2) = estrone + formate + 4 H(2)O + 3
CC       [oxidized NADPH--hemoprotein reductase].
CC       {ECO:0000269|PubMed:27702664}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.46 uM for androstenedione {ECO:0000269|PubMed:27702664};
CC   -!- SUBCELLULAR LOCATION: Membrane; Peripheral membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11511-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11511-2; Sequence=VSP_055583, VSP_055584;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed, including in adult and fetal
CC       brain, placenta, skin fibroblasts, adipose tissue and gonads.
CC       {ECO:0000269|PubMed:2040633, ECO:0000269|PubMed:3018730,
CC       ECO:0000269|PubMed:7690033, ECO:0000269|PubMed:8117272}.
CC   -!- PTM: Phosphorylated in vitro by PKA and PKG/PRKG1. These
CC       phosphorylations inhibit the catalytic activity as measured by
CC       estrone synthesis from androstenedione (36% decrease for PKA and
CC       30% for PKG/PRKG1). {ECO:0000269|PubMed:27702664}.
CC   -!- DISEASE: Aromatase excess syndrome (AEXS) [MIM:139300]: An
CC       autosomal dominant disorder characterized by increased
CC       extraglandular aromatization of steroids that presents with
CC       heterosexual precocity in males and isosexual precocity in
CC       females. Note=The disease is caused by mutations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Aromatase deficiency (AROD) [MIM:613546]: A rare disease
CC       in which fetal androgens are not converted into estrogens due to
CC       placental aromatase deficiency. Thus, pregnant women exhibit a
CC       hirsutism, which spontaneously resolves after post-partum. At
CC       birth, female babies present with pseudohermaphroditism due to
CC       virilization of extern genital organs. In adult females,
CC       manifestations include delay of puberty, breast hypoplasia and
CC       primary amenorrhoea with multicystic ovaries.
CC       {ECO:0000269|PubMed:24705274, ECO:0000269|PubMed:8265607,
CC       ECO:0000269|PubMed:8530621, ECO:0000269|PubMed:9211678}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Aromatase entry;
CC       URL="https://en.wikipedia.org/wiki/Aromatase";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cyp19a1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22246; AAA35557.1; -; mRNA.
DR   EMBL; X13589; CAA31929.1; -; mRNA.
DR   EMBL; M18856; AAA35556.1; -; mRNA.
DR   EMBL; J04127; AAA52132.1; -; mRNA.
DR   EMBL; Y07508; CAA68807.1; -; mRNA.
DR   EMBL; M30804; AAA35728.1; -; Genomic_DNA.
DR   EMBL; M30796; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; M30797; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; M30798; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; M30800; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; M30801; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; M30802; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; M30803; AAA35728.1; JOINED; Genomic_DNA.
DR   EMBL; AY957953; AAX44046.1; -; Genomic_DNA.
DR   EMBL; AC012169; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC020891; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035714; AAH35714.1; -; mRNA.
DR   EMBL; BC107785; AAI07786.1; -; mRNA.
DR   EMBL; M28420; AAA52141.1; -; mRNA.
DR   CCDS; CCDS10139.1; -. [P11511-1]
DR   PIR; A34451; O4HU19.
DR   RefSeq; NP_000094.2; NM_000103.3. [P11511-1]
DR   RefSeq; NP_001334177.1; NM_001347248.1. [P11511-1]
DR   RefSeq; NP_001334178.1; NM_001347249.1. [P11511-1]
DR   RefSeq; NP_001334179.1; NM_001347250.1. [P11511-1]
DR   RefSeq; NP_001334180.1; NM_001347251.1. [P11511-1]
DR   RefSeq; NP_001334181.1; NM_001347252.1. [P11511-1]
DR   RefSeq; NP_001334182.1; NM_001347253.1. [P11511-1]
DR   RefSeq; NP_001334183.1; NM_001347254.1. [P11511-1]
DR   RefSeq; NP_001334184.1; NM_001347255.1. [P11511-1]
DR   RefSeq; NP_001334185.1; NM_001347256.1. [P11511-1]
DR   RefSeq; NP_112503.1; NM_031226.2. [P11511-1]
DR   UniGene; Hs.260074; -.
DR   PDB; 1TQA; Model; -; A=53-495.
DR   PDB; 3EQM; X-ray; 2.90 A; A=1-503.
DR   PDB; 3S79; X-ray; 2.75 A; A=1-503.
DR   PDB; 3S7S; X-ray; 3.21 A; A=1-503.
DR   PDB; 4GL5; X-ray; 3.48 A; A=1-503.
DR   PDB; 4GL7; X-ray; 3.90 A; A=1-503.
DR   PDB; 4KQ8; X-ray; 3.29 A; A=45-503.
DR   PDBsum; 1TQA; -.
DR   PDBsum; 3EQM; -.
DR   PDBsum; 3S79; -.
DR   PDBsum; 3S7S; -.
DR   PDBsum; 4GL5; -.
DR   PDBsum; 4GL7; -.
DR   PDBsum; 4KQ8; -.
DR   ProteinModelPortal; P11511; -.
DR   SMR; P11511; -.
DR   BioGrid; 107960; 5.
DR   IntAct; P11511; 1.
DR   MINT; MINT-4054553; -.
DR   STRING; 9606.ENSP00000260433; -.
DR   BindingDB; P11511; -.
DR   ChEMBL; CHEMBL1978; -.
DR   DrugBank; DB02342; 2-Methoxyestradiol.
DR   DrugBank; DB00357; Aminoglutethimide.
DR   DrugBank; DB01217; Anastrozole.
DR   DrugBank; DB05338; atamestane-plus-toremifene.
DR   DrugBank; DB00443; Betamethasone.
DR   DrugBank; DB04794; Bifonazole.
DR   DrugBank; DB06719; Buserelin.
DR   DrugBank; DB00389; Carbimazole.
DR   DrugBank; DB00269; Chlorotrianisene.
DR   DrugBank; DB00856; Chlorphenesin.
DR   DrugBank; DB00882; Clomifene.
DR   DrugBank; DB00257; Clotrimazole.
DR   DrugBank; DB04839; Cyproterone acetate.
DR   DrugBank; DB01406; Danazol.
DR   DrugBank; DB05804; dehydroepiandrosterone sulfate.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB02901; Dihydrotestosterone.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB00858; Drostanolone.
DR   DrugBank; DB01127; Econazole.
DR   DrugBank; DB00974; Edetic Acid.
DR   DrugBank; DB00292; Etomidate.
DR   DrugBank; DB00926; Etretinate.
DR   DrugBank; DB00990; Exemestane.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB01006; Letrozole.
DR   DrugBank; DB01227; Levomethadyl Acetate.
DR   DrugBank; DB00367; Levonorgestrel.
DR   DrugBank; DB00358; Mefloquine.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB00333; Methadone.
DR   DrugBank; DB06710; Methyltestosterone.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB05749; MPI-674.
DR   DrugBank; DB08804; Nandrolone decanoate.
DR   DrugBank; DB00984; Nandrolone phenpropionate.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB09389; Norgestrel.
DR   DrugBank; DB01229; Paclitaxel.
DR   DrugBank; DB00481; Raloxifene.
DR   DrugBank; DB05875; substance P.
DR   DrugBank; DB06147; Sulfathiazole.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00857; Terbinafine.
DR   DrugBank; DB00894; Testolactone.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB01007; Tioconazole.
DR   DrugBank; DB00072; Trastuzumab.
DR   DrugBank; DB00197; Troglitazone.
DR   GuidetoPHARMACOLOGY; 1362; -.
DR   iPTMnet; P11511; -.
DR   PhosphoSitePlus; P11511; -.
DR   BioMuta; CYP19A1; -.
DR   DMDM; 117293; -.
DR   PaxDb; P11511; -.
DR   PeptideAtlas; P11511; -.
DR   PRIDE; P11511; -.
DR   DNASU; 1588; -.
DR   Ensembl; ENST00000396402; ENSP00000379683; ENSG00000137869. [P11511-1]
DR   Ensembl; ENST00000396404; ENSP00000379685; ENSG00000137869. [P11511-1]
DR   Ensembl; ENST00000405913; ENSP00000383930; ENSG00000137869. [P11511-2]
DR   Ensembl; ENST00000557858; ENSP00000452627; ENSG00000137869. [P11511-2]
DR   Ensembl; ENST00000559878; ENSP00000453149; ENSG00000137869. [P11511-1]
DR   GeneID; 1588; -.
DR   KEGG; hsa:1588; -.
DR   UCSC; uc001zyz.5; human. [P11511-1]
DR   CTD; 1588; -.
DR   DisGeNET; 1588; -.
DR   GeneCards; CYP19A1; -.
DR   HGNC; HGNC:2594; CYP19A1.
DR   HPA; CAB000355; -.
DR   HPA; HPA051194; -.
DR   MalaCards; CYP19A1; -.
DR   MIM; 107910; gene.
DR   MIM; 139300; phenotype.
DR   MIM; 613546; phenotype.
DR   neXtProt; NX_P11511; -.
DR   OpenTargets; ENSG00000137869; -.
DR   Orphanet; 91; Aromatase deficiency.
DR   Orphanet; 178345; Aromatase excess syndrome.
DR   PharmGKB; PA27091; -.
DR   eggNOG; KOG0157; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00840000129915; -.
DR   HOGENOM; HOG000111912; -.
DR   HOVERGEN; HBG050750; -.
DR   InParanoid; P11511; -.
DR   KO; K07434; -.
DR   OMA; PELWKTT; -.
DR   OrthoDB; EOG091G056R; -.
DR   PhylomeDB; P11511; -.
DR   TreeFam; TF352039; -.
DR   BioCyc; MetaCyc:HS06413-MONOMER; -.
DR   BRENDA; 1.14.14.14; 2681.
DR   Reactome; R-HSA-193144; Estrogen biosynthesis.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   SABIO-RK; P11511; -.
DR   SIGNOR; P11511; -.
DR   ChiTaRS; CYP19A1; human.
DR   EvolutionaryTrace; P11511; -.
DR   GeneWiki; Aromatase; -.
DR   GenomeRNAi; 1588; -.
DR   PRO; PR:P11511; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000137869; -.
DR   CleanEx; HS_CYP19A1; -.
DR   ExpressionAtlas; P11511; baseline and differential.
DR   Genevisible; P11511; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:LIFEdb.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0070330; F:aromatase activity; IDA:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016712; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; TAS:UniProtKB.
DR   GO; GO:0019825; F:oxygen binding; TAS:ProtInc.
DR   GO; GO:0008395; F:steroid hydroxylase activity; TAS:Reactome.
DR   GO; GO:0006710; P:androgen catabolic process; IDA:CAFA.
DR   GO; GO:0006703; P:estrogen biosynthetic process; TAS:Reactome.
DR   GO; GO:0030540; P:female genitalia development; IEA:Ensembl.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0030879; P:mammary gland development; IEA:Ensembl.
DR   GO; GO:0002677; P:negative regulation of chronic inflammatory response; IEA:Ensembl.
DR   GO; GO:0010760; P:negative regulation of macrophage chemotaxis; IEA:Ensembl.
DR   GO; GO:2000866; P:positive regulation of estradiol secretion; IDA:CAFA.
DR   GO; GO:0060736; P:prostate gland growth; IEA:Ensembl.
DR   GO; GO:0006694; P:steroid biosynthetic process; TAS:ProtInc.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   GO; GO:0061370; P:testosterone biosynthetic process; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Heme; Iron; Membrane;
KW   Metal-binding; Monooxygenase; Oxidoreductase; Polymorphism;
KW   Pseudohermaphroditism; Reference proteome.
FT   CHAIN         1    503       Aromatase.
FT                                /FTId=PRO_0000051955.
FT   METAL       437    437       Iron (heme axial ligand).
FT   BINDING     309    309       Substrate.
FT   BINDING     374    374       Substrate; via amide nitrogen.
FT   VAR_SEQ     210    218       ESAIVVKIQ -> GTEIFTLTS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_055583.
FT   VAR_SEQ     219    503       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_055584.
FT   VARIANT      39     39       W -> R (in dbSNP:rs2236722).
FT                                {ECO:0000269|PubMed:10956405,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_023428.
FT   VARIANT     192    192       R -> H (in AROD; strongly reduced
FT                                aromatase activity; 81% reduction of
FT                                androstenedione metabolism compared to
FT                                wild-type; dbSNP:rs765057534).
FT                                {ECO:0000269|PubMed:24705274}.
FT                                /FTId=VAR_072784.
FT   VARIANT     201    201       T -> M (in dbSNP:rs28757184).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_023429.
FT   VARIANT     264    264       R -> C (1.6 fold decrease in affinity for
FT                                androstenedione substrate; slightly
FT                                affects PKA-mediated reduction in
FT                                catalytic activity as measured in vitro
FT                                by estrone synthesis from androstenedione
FT                                (49% decrease compared with 36% for the
FT                                wild-type protein); no effect on PKG/
FT                                PRKG1-mediated reduction in catalytic
FT                                activity in vitro; dbSNP:rs700519).
FT                                {ECO:0000269|PubMed:10956405,
FT                                ECO:0000269|PubMed:27702664,
FT                                ECO:0000269|PubMed:2848247,
FT                                ECO:0000269|PubMed:3653507,
FT                                ECO:0000269|PubMed:9352581,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_018406.
FT   VARIANT     264    264       R -> H (2.5 fold decrease in affinity for
FT                                androstenedione substrate; slightly
FT                                affects PKA-mediated reduction in
FT                                catalytic activity as measured by estrone
FT                                synthesis from androstenedione in vitro
FT                                (28% decrease compared with 36% for the
FT                                wild-type protein) and PKG/PRKG1-mediated
FT                                reduction in catalytic activity in vitro
FT                                (15% decrease compared with 30% for the
FT                                wild-type protein); dbSNP:rs2304462).
FT                                {ECO:0000269|PubMed:27702664}.
FT                                /FTId=VAR_077526.
FT   VARIANT     365    365       R -> Q (in AROD; 0.4% of wild-type
FT                                activity; dbSNP:rs80051519).
FT                                {ECO:0000269|PubMed:9211678}.
FT                                /FTId=VAR_016962.
FT   VARIANT     375    375       R -> C (in AROD; dbSNP:rs121434536).
FT                                {ECO:0000269|PubMed:8530621}.
FT                                /FTId=VAR_016963.
FT   VARIANT     375    375       R -> L. {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054152.
FT   VARIANT     435    435       R -> C (in AROD; 1.1% of wild-type
FT                                activity; dbSNP:rs121434534).
FT                                {ECO:0000269|PubMed:8265607}.
FT                                /FTId=VAR_016964.
FT   VARIANT     437    437       C -> Y (in AROD; complete loss of
FT                                activity; dbSNP:rs78310315).
FT                                {ECO:0000269|PubMed:8265607}.
FT                                /FTId=VAR_016965.
FT   CONFLICT    496    496       N -> S (in Ref. 1; AAA35557/CAA31929).
FT                                {ECO:0000305}.
FT   STRAND       54     56       {ECO:0000244|PDB:3S79}.
FT   HELIX        57     68       {ECO:0000244|PDB:3S79}.
FT   HELIX        70     80       {ECO:0000244|PDB:3S79}.
FT   STRAND       83     97       {ECO:0000244|PDB:3S79}.
FT   HELIX       100    108       {ECO:0000244|PDB:3S79}.
FT   HELIX       110    112       {ECO:0000244|PDB:3S79}.
FT   HELIX       119    125       {ECO:0000244|PDB:3S79}.
FT   STRAND      130    132       {ECO:0000244|PDB:3S79}.
FT   HELIX       138    151       {ECO:0000244|PDB:3S79}.
FT   HELIX       155    172       {ECO:0000244|PDB:3S79}.
FT   HELIX       173    177       {ECO:0000244|PDB:3S79}.
FT   STRAND      183    185       {ECO:0000244|PDB:3S7S}.
FT   HELIX       187    203       {ECO:0000244|PDB:3S79}.
FT   HELIX       210    227       {ECO:0000244|PDB:3S79}.
FT   HELIX       232    236       {ECO:0000244|PDB:3S79}.
FT   HELIX       238    240       {ECO:0000244|PDB:3S79}.
FT   HELIX       242    267       {ECO:0000244|PDB:3S79}.
FT   TURN        270    275       {ECO:0000244|PDB:3S79}.
FT   HELIX       278    287       {ECO:0000244|PDB:3S79}.
FT   TURN        288    290       {ECO:0000244|PDB:3EQM}.
FT   HELIX       293    324       {ECO:0000244|PDB:3S79}.
FT   HELIX       326    339       {ECO:0000244|PDB:3S79}.
FT   TURN        340    342       {ECO:0000244|PDB:3S79}.
FT   HELIX       347    349       {ECO:0000244|PDB:3S79}.
FT   TURN        350    352       {ECO:0000244|PDB:3S79}.
FT   HELIX       354    366       {ECO:0000244|PDB:3S79}.
FT   STRAND      373    376       {ECO:0000244|PDB:3S79}.
FT   STRAND      381    383       {ECO:0000244|PDB:3S79}.
FT   STRAND      386    388       {ECO:0000244|PDB:3S79}.
FT   STRAND      393    396       {ECO:0000244|PDB:3S79}.
FT   HELIX       398    401       {ECO:0000244|PDB:3S79}.
FT   TURN        402    404       {ECO:0000244|PDB:3S79}.
FT   HELIX       415    418       {ECO:0000244|PDB:3S79}.
FT   TURN        424    426       {ECO:0000244|PDB:3S79}.
FT   HELIX       433    435       {ECO:0000244|PDB:4KQ8}.
FT   HELIX       440    455       {ECO:0000244|PDB:3S79}.
FT   STRAND      458    463       {ECO:0000244|PDB:3S79}.
FT   TURN        468    470       {ECO:0000244|PDB:3S79}.
FT   STRAND      473    481       {ECO:0000244|PDB:3S79}.
FT   STRAND      483    485       {ECO:0000244|PDB:4KQ8}.
FT   STRAND      490    494       {ECO:0000244|PDB:3S79}.
SQ   SEQUENCE   503 AA;  57883 MW;  9BD9B28651D9A69A CRC64;
     MVLEMLNPIH YNITSIVPEA MPAATMPVLL LTGLFLLVWN YEGTSSIPGP GYCMGIGPLI
     SHGRFLWMGI GSACNYYNRV YGEFMRVWIS GEETLIISKS SSMFHIMKHN HYSSRFGSKL
     GLQCIGMHEK GIIFNNNPEL WKTTRPFFMK ALSGPGLVRM VTVCAESLKT HLDRLEEVTN
     ESGYVDVLTL LRRVMLDTSN TLFLRIPLDE SAIVVKIQGY FDAWQALLIK PDIFFKISWL
     YKKYEKSVKD LKDAIEVLIA EKRRRISTEE KLEECMDFAT ELILAEKRGD LTRENVNQCI
     LEMLIAAPDT MSVSLFFMLF LIAKHPNVEE AIIKEIQTVI GERDIKIDDI QKLKVMENFI
     YESMRYQPVV DLVMRKALED DVIDGYPVKK GTNIILNIGR MHRLEFFPKP NEFTLENFAK
     NVPYRYFQPF GFGPRGCAGK YIAMVMMKAI LVTLLRRFHV KTLQGQCVES IQKIHDLSLH
     PDETKNMLEM IFTPRNSDRC LEH
//
